Adbry (Tralokinumab) for the Treatment of Atopic Dermatitia
Speaker: Mariola Vazquez, Pharm.D.; Medical Outcomes Liaison, Leo Pharma
Description: ADBRYTM (tralokinumab-ldrm), the first and only biologic developed to specifically bind to and inhibit the interleukin-13 cytokine, has been approved by the United States Food and Drug Administration for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRYTM can be used with or without topical corticosteroids.
Following this webinar participants will be able to:
- Discuss the pathophysiology, clinical presentation and burden of disease associated with Atopic Dermatitis.
- Understand the role of IL-13 and ADBRY's targeted mechanism on this cytokine.
- Review the clinical efficacy and safety of ADBRY as a treatment option for Atopic Dermatitis.
- Discuss the role of ADBRY in the current disease landscape.
Virtual Platform: GoToWebinar
Target Audience: Pharmacists, Dermatologists, Allergists, Immunologists
Date: Thursday, October 27, 2022
Time: 12:00pm EST
CME/CE: 0 hrs
IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder.
This webinar is sponsored by: